Urinary Neutrophil Gelatinase-Associated Lipocalin to Monitor Lupus Nephritis Disease Activity

Overview

Journal Biomark Insights

Publisher Sage Publications

Date 2015 Sep 24

PMID 26396491

Citations 1

Authors

Hani Susianti

Jullyanny W Wijaya

Ati Rastini

Kusworini Handono

Atma Gunawan

Handono Kalim

Affiliations

Soon will be listed here.

Abstract

Background: This study was conducted to determine whether there is an association between urinary neutrophil gelatinase-associated lipocalin (uNGAL) and urinary transforming growth factor-β1 (uTGF-β1) with lupus nephritis (LN) disease activity.

Methods: Urine samples from 18 LN patients were collected every month for six months then examined for uNGAL, uTGF-β1, and renal domain Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score.

Results: The uNGAL levels were significantly different between active and inactive LN (P < 0.05). uTGF-β1 levels were not different between active and inactive LN (P < 0.05). There was a significant correlation between uNGAL levels and renal domain SLEDAI score (r = 0.417, P < 0.05). There was no correlation between uTGF-β1 levels and renal domain SLEDAI score (r = 0.031, P < 0.05).

Conclusion: uNGAL is better than uTGF-β1 for differentiation of active and inactive LN. uNGAL can be considered as a biomarker to monitor LN disease activity.

Citing Articles

Rapid detection of urinary soluble intercellular adhesion molecule-1 for determination of lupus nephritis activity.

Wang Y, Tao Y, Liu Y, Zhao Y, Song C, Zhou B Medicine (Baltimore). 2018; 97(26):e11287.

PMID: 29953010 PMC: 6039621. DOI: 10.1097/MD.0000000000011287.

References

Rubinstein T, Pitashny M, Levine B, Schwartz N, Schwartzman J, Weinstein E . Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford). 2010; 49(5):960-71. PMC: 2853702. DOI: 10.1093/rheumatology/kep468. View

Susianti H, Iriane V, Dharmanata S, Handono K, Widijanti A, Gunawan A . Analysis of urinary TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. Pathophysiology. 2015; 22(1):65-71. DOI: 10.1016/j.pathophys.2014.12.003. View

Soni S, Cruz D, Bobek I, Chionh C, Nalesso F, Lentini P . NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol. 2009; 42(1):141-50. DOI: 10.1007/s11255-009-9608-z. View

Fukuda N, Tahira Y, Matsuda H, Matsumoto K . Transforming growth factor-beta as a treatment target in renal diseases. J Nephrol. 2009; 22(6):708-15. View

Ma S . Neutrophil gelatinase-associated lipocalin as a predictor of adverse renal outcomes in immunoglobulin A nephropathy. Korean J Intern Med. 2015; 30(3):305-7. PMC: 4438284. DOI: 10.3904/kjim.2015.30.3.305. View

Tang S, Lui S, Lai K . Pathogenesis of lupus nephritis: an update. Nephrology (Carlton). 2005; 10(2):174-9. DOI: 10.1111/j.1440-1797.2005.00392.x. View

Mishra J, Dent C, Tarabishi R, Mitsnefes M, Ma Q, Kelly C . Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005; 365(9466):1231-8. DOI: 10.1016/S0140-6736(05)74811-X. View

Ohtsuka K, GRAY J, Stimmler M, Toro B, Horwitz D . Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1998; 160(5):2539-45. View

Tamaki K, Okuda S, Ando T, Iwamoto T, Nakayama M, Fujishima M . TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy. Kidney Int. 1994; 45(2):525-36. DOI: 10.1038/ki.1994.68. View

10.

Hinze C, Suzuki M, Klein-Gitelman M, Passo M, Olson J, Singer N . Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 2009; 60(9):2772-81. PMC: 3064260. DOI: 10.1002/art.24751. View

11.

Devarajan P . Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl. 2008; 241:89-94. PMC: 2528839. DOI: 10.1080/00365510802150158. View

12.

Hammad A, Youssef H, El-Arman M . Transforming growth factor beta 1 in children with systemic lupus erythematosus: a possible relation with clinical presentation of lupus nephritis. Lupus. 2006; 15(9):608-12. DOI: 10.1177/0961203306071873. View

13.

Kohut E, Hajdu M, Gergely P, Gopcsa L, Kilian K, Paloczi K . Expression of TGFbeta1 and its signaling components by peripheral lymphocytes in systemic lupus erythematosus. Pathol Oncol Res. 2008; 15(2):251-6. DOI: 10.1007/s12253-008-9119-8. View

14.

Tamaki K, Okuda S, Miyazono K, Nakayama M, Fujishima M . Matrix-associated latent TGF-beta with latent TGF-beta binding protein in the progressive process in adriamycin-induced nephropathy. Lab Invest. 1995; 73(1):81-9. View

15.

Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M . Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum. 2007; 56(6):1894-903. DOI: 10.1002/art.22594. View

16.

Goumenos D, Tsakas S, El Nahas A, Alexandri S, Oldroyd S, Kalliakmani P . Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant. 2002; 17(12):2145-52. DOI: 10.1093/ndt/17.12.2145. View

17.

Caletti M, Balestracci A, Roy A . Levels of urinary transforming growth factor beta-1 in children with D+ hemolytic uremic syndrome. Pediatr Nephrol. 2010; 25(6):1177-80. DOI: 10.1007/s00467-009-1434-0. View

18.

Budu-Grajdeanu P, Schugart R, Friedman A, Birmingham D, Rovin B . Mathematical framework for human SLE Nephritis: disease dynamics and urine biomarkers. Theor Biol Med Model. 2010; 7:14. PMC: 2877652. DOI: 10.1186/1742-4682-7-14. View

19.

Goumenos D, Kalliakmani P, Tsakas S, Sotsiou F, Vlachojannis J . Urinary Transforming Growth Factor-beta 1 as a marker of response to immunosuppressive treatment, in patients with crescentic nephritis. BMC Nephrol. 2005; 6:16. PMC: 1327665. DOI: 10.1186/1471-2369-6-16. View

20.

Yamamoto K, Loskutoff D . Expression of transforming growth factor-beta and tumor necrosis factor-alpha in the plasma and tissues of mice with lupus nephritis. Lab Invest. 2000; 80(10):1561-70. DOI: 10.1038/labinvest.3780166. View